Schizophrenia/Psychosis

An overview of the first study to demonstrate benefits of sodium benzoate--an NMDA enhancer--in patients with clozapine-resistant schizophrenia.

Functional connectivity is a “rapidly developing scientific story.” And for psychiatrists, it is a story worth following.

New research looks at the effects of CBD on positive and negative psychotic symptoms, cognitive performance, level of functioning, and the treating psychiatrist’s overall clinical impression.

Clinicians should be aware of recent research that highlights an important, although rare, adverse effect of this medication used to treat glaucoma.

Imagination and psychosis are different categories of experience, and should not be confused or conflated.

Is oxidative stress a therapeutic target in schizophrenia?

What the nose knows in patients with schizophrenia.

What does the evidence tell us about digital sensors for treatment adherence in patients with schizophrenia and other psychiatric disorders?

How to decrease recidivism for individuals with serious mental illnesses who are released from jails or prisons or discharged from hospitals? Here are several effective mechanisms.

What are the strongest predictors of suicidality in schizophrenia?

New evidence links vitamin D status with cognition in patients with psychosis.

This article describes challenges for psychiatrists striving to ensure informed consent for, and for patients who may lack full appreciation of the risks and benefits of, neurostimulation.

Which genes have recently been associated with TD? That question and more in this quiz.

New evidence bolsters the reputation of clozapine as the “gold-standard” antipsychotic for patients with treatment-resistant schizophrenia.

Tips for having a balanced and comprehensive risk-to-benefit discussion with competent patients who want to stop their medications.

Is an effective, well-tolerated treatment for the negative symptoms of schizophrenia on the horizon?

No, there is no generalized epidemic of mental illness in the US, nor credible evidence that psychiatric drugs are driving up rates or severity of mental illness. But there is an urgent need for more and better treatment of psychiatric disorders.

What factors come into play in the diagnosis of tardive dyskinesia? How is TD distinguished from other movement disorders? Find out more in this quiz.

This article focuses on appropriate versus inappropriate use of antipsychotics, the importance of careful assessment, and the consequences of not treating.

Schizophrenia and T2 DM risk; short-term weight gain with specific antipsychotics; interventions to reduce weight and/or metabolic abnormalities. . .answers here.

Six fundamental assumptions underlie the medical model most psychiatrists use in their clinical work.

New findings support the involvement of microbiota alterations in psychosis-and point to novel treatments.

Which psychotropic combinations unlock the door to successful treatment?

Do prolactin-elevating antipsychotics put women at risk for endometrial cancer?

Which gene is not associated with risk for the development of TD? What is the prevalence of TD in patients with schizophrenia treated with antipsychotics? Those questions and more in this quiz.